AMINOSYN II 8.5% W/ELECTROLYTES
Clinical safety rating: caution
Comprehensive clinical and safety monograph for AMINOSYN II 8.5% W/ELECTROLYTES (AMINOSYN II 8.5% W/ELECTROLYTES).
Amino acids serve as substrates for protein synthesis and provide nitrogen for metabolic processes. Electrolytes maintain acid-base balance and osmotic pressure.
| Metabolism | Amino acids are metabolized in the liver via deamination, transamination, and urea cycle; electrolytes are excreted or reabsorbed by the kidneys. |
| Excretion | Renal >90% (as amino acids and metabolites); fecal <5% |
| Half-life | Variable; amino acids typically have half-lives of minutes to hours; free amino acids in plasma have t1/2 of 10-30 minutes for most |
| Protein binding | Minimal (most amino acids are not protein-bound; some metabolites may bind weakly); albumin binding: <10% |
| Volume of Distribution | 0.3-0.5 L/kg (distributes primarily into extracellular water and total body water; reflects rapid distribution into lean body mass) |
| Bioavailability | Intravenous: 100% (only route of administration) |
| Onset of Action | Intravenous: Immediate; amino acids appear in plasma within 5-10 minutes |
| Duration of Action | Intravenous: 4-6 hours (continuous infusion needed to maintain nitrogen balance); clinical effect is sustained as long as infusion continues |
1 to 1.5 g amino acids/kg/day intravenously, typically infused over 12-24 hours.
| Dosage form | INJECTABLE |
| Renal impairment | For GFR < 50 mL/min, reduce dose to 0.5-1 g amino acids/kg/day and monitor BUN; for GFR < 15 mL/min, use only if on renal replacement therapy, with dose of 0.5-0.8 g/kg/day. |
| Liver impairment | Child-Pugh Class B: reduce dose to 0.5-0.8 g amino acids/kg/day and monitor ammonia; Child-Pugh Class C: avoid or use with extreme caution at 0.5 g/kg/day, with close monitoring of ammonia levels. |
| Pediatric use | Weight-based: initial dose 0.5-1 g amino acids/kg/day intravenously, titrate to desired nitrogen balance, not to exceed 2 g/kg/day; for neonates and preterm infants, start at 0.5 g/kg/day and increase by 0.5 g/kg/day to target 1-1.5 g/kg/day. |
| Geriatric use | Elderly patients: start at lower end of dosing (0.5-1 g/kg/day) with gradual titration; monitor renal function, fluid status, and metabolic parameters due to increased risk of fluid overload and electrolyte imbalances. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for AMINOSYN II 8.5% W/ELECTROLYTES (AMINOSYN II 8.5% W/ELECTROLYTES).
| Breastfeeding | Aminosyn II components (amino acids, electrolytes) are normally present in human milk at low concentrations. No specific M/P ratio data available. Intravenous administration may increase maternal levels, but amounts transferred to milk are likely negligible. Considered compatible with breastfeeding when used for maternal nutritional support. |
| Teratogenic Risk | Aminosyn II 8.5% with Electrolytes is a parenteral nutrition solution containing amino acids and electrolytes. No specific teratogenic effects have been reported with standard use during pregnancy. However, amino acid imbalances or hyperammonemia could pose risks. The manufacturer advises caution in pregnancy; use only if clearly needed. Fetal risk cannot be ruled out; consider trimester-specific nutritional requirements. |
■ FDA Black Box Warning
Not for use in patients with inborn errors of amino acid metabolism, hepatic coma, or severe renal failure.
| Serious Effects |
["Hypersensitivity to any component","Inborn errors of amino acid metabolism","Severe hepatic disease with encephalopathy","Severe renal failure without dialysis","Hyperkalemia","Hypernatremia"]
| Precautions | ["Risk of hyperammonemia in hepatic impairment","Electrolyte imbalances (hyperkalemia, hypernatremia)","Volume overload in renal or cardiac insufficiency","Monitor serum electrolytes, BUN, ammonia, and glucose"] |
| Food/Dietary | Do not mix with other medications in the infusion bag unless approved by a pharmacist. No oral food interactions as this is for parenteral use only. |
Loading safety data…
| Fetal Monitoring | Monitor serum electrolytes, acid-base balance, serum ammonia (especially in patients with hepatic impairment), renal function (BUN, creatinine), and blood glucose. Monitor for signs of fluid overload or electrolyte disturbances. Fetal assessment as per standard obstetric care. |
| Fertility Effects | Amino acids and electrolytes in parenteral nutrition are essential for normal reproductive function. No direct adverse fertility effects reported. Correction of maternal malnutrition may improve fertility. |
| Clinical Pearls | Contains 8.5% amino acids with electrolytes, used for parenteral nutrition. Monitor serum electrolytes, fluid balance, and renal function. Adjust infusion rate to avoid hyperglycemia or volume overload. Do not administer peripherally due to high osmolality (approx. 850 mOsm/L). Use with lipid emulsion to prevent essential fatty acid deficiency. |
| Patient Advice | This medication is given through a vein to provide protein and nutrients when you cannot eat. · Report any swelling, shortness of breath, or weight gain, as these may indicate fluid overload. · Your blood sugar and electrolyte levels will be checked regularly during treatment. · Do not stop or change the infusion rate without consulting your healthcare provider. · Tell your doctor if you have a history of kidney disease, diabetes, or electrolyte imbalances. |